Compare TRIP & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRIP | AMPH |
|---|---|---|
| Founded | 2000 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2011 | 2005 |
| Metric | TRIP | AMPH |
|---|---|---|
| Price | $9.77 | $18.77 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 7 |
| Target Price | $14.88 | ★ $30.29 |
| AVG Volume (30 Days) | ★ 4.1M | 525.8K |
| Earning Date | 01-01-0001 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 675.00 | N/A |
| EPS | 0.31 | ★ 2.03 |
| Revenue | ★ $1,556,000,000.00 | $719,887,000.00 |
| Revenue This Year | $3.33 | $7.34 |
| Revenue Next Year | $5.12 | $4.81 |
| P/E Ratio | $31.71 | ★ $9.25 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.46 | $18.52 |
| 52 Week High | $20.16 | $31.26 |
| Indicator | TRIP | AMPH |
|---|---|---|
| Relative Strength Index (RSI) | 32.69 | 23.66 |
| Support Level | $9.54 | N/A |
| Resistance Level | $15.37 | $28.56 |
| Average True Range (ATR) | 0.47 | 1.22 |
| MACD | 0.10 | -0.69 |
| Stochastic Oscillator | 8.16 | 2.18 |
Tripadvisor is the world's leading travel metasearch company. Its platform offers 1 billion reviews and information on several million accommodations, restaurants, experiences, airlines, and cruises. In 2024, 52% of revenue came from the company's core Brand Tripadvisor segment, which includes hotel revenue generated through advertising on its metasearch platform (33% of 2024 sales). Viator, its experiences brand, was 46% of revenue in 2024, and TheFork, its dining brand, represented 10% of sales (about 8% of revenue were intersegment, which are eliminated from consolidated revenue).
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.